Novartis

This week, Reuters reported that Swiss drugmaker Novartis AG said it will acquire German biotech MorphoSys AG, a developer of cancer treatments, for Euro2.7 billion (US$2.9 billion). The move by Novartis aims to add a promising rare bone marrow cancer treatment candidate to its portfolio. The companies said that shareholders of the German firm would…

Read more →